Preface biomarkers in critical illness.

[1]  S. Lapinsky,et al.  Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis* , 2010, Critical care medicine.

[2]  Anand Kumar,et al.  A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study , 2010, Critical care medicine.

[3]  D. Hoban,et al.  Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) , 2010, Antimicrobial Agents and Chemotherapy.

[4]  Joshua A. Doherty,et al.  Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis , 2010, Antimicrobial Agents and Chemotherapy.

[5]  Anand Kumar,et al.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. , 2009, Chest.

[6]  J. Solomkin,et al.  Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. , 2009, International journal of antimicrobial agents.

[7]  Ronald Anderson,et al.  Therapy for pneumococcal bacteremia: monotherapy or combination therapy? , 2009, Current opinion in infectious diseases.

[8]  Vance G Fowler,et al.  Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Levine,et al.  Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates , 2008, The Journal of antimicrobial chemotherapy.

[10]  N. Safdar,et al.  Combination Antimicrobial Therapy for Gram-Negative Infections: What Is the Evidence? , 2007 .

[11]  P. Barie,et al.  Management of Severe Sepsis of Abdominal Origin , 2007, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[12]  L. Cosler,et al.  Comparison of β-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia , 2007, Antimicrobial Agents and Chemotherapy.

[13]  Meta-analysis of procalcitonin for sepsis detection. , 2007, The Lancet. Infectious diseases.

[14]  J. Rello,et al.  Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock* , 2007, Critical care medicine.

[15]  S. Blot,et al.  Antibiotic therapy for community-acquired pneumonia with septic shock: follow the guidelines. , 2007, Critical care medicine.

[16]  A. Anzueto,et al.  Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  D. Healy.  Macrolide immunomodulation of chronic respiratory diseases , 2007, Current infectious disease reports.

[18]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[20]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[21]  Soumitra R. Eachempati,et al.  Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. , 2006, Surgical infections.

[22]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[23]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[24]  J. Rello,et al.  Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Z. Bartoszewicz,et al.  Biomarker-based risk assessment model in acute pulmonary embolism. , 2005, European heart journal.

[26]  James A Russell,et al.  Early changes in organ function predict eventual survival in severe sepsis* , 2005, Critical care medicine.

[27]  Sanjay Saint,et al.  Clinical and economic consequences of ventilator-associated pneumonia: A systematic review , 2005, Critical care medicine.

[28]  M. Béné,et al.  Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis , 2005, Critical care medicine.

[29]  J. Douketis,et al.  The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  J. Griffith,et al.  Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[31]  U. Schöffel,et al.  Principles and limitations of operative management of intraabdominal infections , 1990, World Journal of Surgery.

[32]  J. Schrenzel,et al.  A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Bonten,et al.  Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review , 2004, Critical care medicine.

[34]  D. Snydman,et al.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. , 2004, American journal of respiratory and critical care medicine.

[35]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Handelsman,et al.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. , 2004, The Lancet. Infectious diseases.

[37]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[38]  Claude D Martin,et al.  Clinical and Therapeutic Features of Nonpostoperative Nosocomial Intra-abdominal Infections , 2004 .

[39]  F. Nepveu,et al.  Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. , 2004, Canadian respiratory journal.

[40]  J. Garnacho-Montero,et al.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.

[41]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[42]  E. P. Dellinger,et al.  Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  A. Torbicki,et al.  Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. , 2003, Chest.

[44]  Victoria J. Fraser,et al.  Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center* , 2003, Critical care medicine.

[45]  D. Cook,et al.  Measures, markers, and mediators: Toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25–26, 2000 , 2003, Critical care medicine.

[46]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[47]  C. Perry,et al.  Cefepime: a review of its use in the management of hospitalized patients with pneumonia. , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[48]  M. Olschewski,et al.  Importance of Cardiac Troponins I and T in Risk Stratification of Patients With Acute Pulmonary Embolism , 2002, Circulation.

[49]  J. Hassett,et al.  Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. , 2002, International journal of antimicrobial agents.

[50]  A. Nathens,et al.  The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. , 2002, Surgical infections.

[51]  S. Dzik.  Early goal-directed therapy in the treatment of severe sepsis and septic shock , 2002 .

[52]  R. Bellomo,et al.  Pharmacological Principles of Antibiotic Prescription in the Critically Ill , 2002, Anaesthesia and intensive care.

[53]  L. Olaison,et al.  Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  C. Ohmann,et al.  The microbiology of postoperative peritonitis. , 2001 .

[55]  R. Wunderink,et al.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. , 2001, Archives of internal medicine.

[56]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[57]  D. Nicolau,et al.  Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. , 2001, International journal of antimicrobial agents.

[58]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[59]  T. Calandra,et al.  Antibiotics in sepsis , 2001, Intensive Care Medicine.

[60]  E. Bouza,et al.  Monotherapy versus combination therapy for bacterial infections. , 2000, The Medical clinics of North America.

[61]  A. Buchwald,et al.  Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. , 2000, Journal of the American College of Cardiology.

[62]  P. Lipsett,et al.  Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections , 2000, Annals of surgery.

[63]  J. Carlet,et al.  Monotherapy with a Broad-Spectrum Beta-Lactam Is as Effective as Its Combination with an Aminoglycoside in Treatment of Severe Generalized Peritonitis: a Multicenter Randomized Controlled Trial , 2000, Antimicrobial Agents and Chemotherapy.

[64]  R. Hancock,et al.  Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[65]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[66]  A. Po,et al.  Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. , 1999, The Journal of antimicrobial chemotherapy.

[67]  H. Forssell,et al.  Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. , 1999, The European journal of surgery = Acta chirurgica.

[68]  M. Mufson,et al.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. , 1999, The American journal of medicine.

[69]  D. Cook,et al.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. , 1999, American journal of respiratory and critical care medicine.

[70]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[71]  A P Wheeler,et al.  Treating patients with severe sepsis. , 1999, The New England journal of medicine.

[72]  V. Yu,et al.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. , 1999, International Journal of Antimicrobial Agents.

[73]  J. Mouton.  Combination therapy as a tool to prevent emergence of bacterial resistance , 1999, Infection.

[74]  A. Bolger,et al.  Diagnosis and management of infective endocarditis and its complications. , 1998, Circulation.

[75]  D. Durack,et al.  Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  R. Chioléro,et al.  Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis , 1998, Antimicrobial Agents and Chemotherapy.

[77]  D. Cook,et al.  Risk factors for ICU-acquired pneumonia. , 1998, JAMA.

[78]  P E Ochsner,et al.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. , 1998, JAMA.

[79]  R N Jones,et al.  National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. , 1998, Diagnostic microbiology and infectious disease.

[80]  J. Marshall,et al.  Tertiary Peritonitis: Clinical Features of a Complex Nosocomial Infection , 1993, World Journal of Surgery.

[81]  P. Barie,et al.  A Randomized, Double-blind Clinical Trial Comparing Cefepime Plus Metronidazole With Imipenem-Cilastatin in the Treatment of Complicated Intra-abdominal Infections , 1997 .

[82]  B. Sieger,et al.  Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. , 1997, Critical care medicine.

[83]  D. Bates,et al.  Epidemiology of sepsis syndrome in 8 academic medical centers. , 1997, JAMA.

[84]  E. Taylor,et al.  A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. , 1997, The Journal of antimicrobial chemotherapy.

[85]  L. Leibovici,et al.  Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study , 1997, Antimicrobial agents and chemotherapy.

[86]  F. V. van Tiel,et al.  Indications for antibiotic use in ICU patients: a one-year prospective surveillance. , 1997, The Journal of antimicrobial chemotherapy.

[87]  Hollander,et al.  Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model , 1997, Antimicrobial agents and chemotherapy.

[88]  I. Ocaña,et al.  Effectiveness of Cloxacillin with and without Gentamicin in Short-Term Therapy for Right-Sided Staphylococcus aureus Endocarditis , 1996, Annals of Internal Medicine.

[89]  J. Gatell,et al.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. , 1996, Archives of internal medicine.

[90]  P. Montravers,et al.  Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  Claude Carbón,et al.  Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model , 1996, Antimicrobial agents and chemotherapy.

[92]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.

[93]  F A Manian,et al.  Loss of Antimicrobial Susceptibility in Aerobic Gram-Negative Bacilli Repeatedly Isolated From Patients in Intensive-Care Units , 1996, Infection Control & Hospital Epidemiology.

[94]  J. Bohnen,et al.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. , 1996, Annals of surgery.

[95]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[96]  A. Viste,et al.  A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. , 1996, Scandinavian journal of infectious diseases.

[97]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[98]  S. Wilson,et al.  Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[99]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[100]  H. Lode,et al.  Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  P. Schauer,et al.  Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. , 1995, The American surgeon.

[102]  J. Solomkin,et al.  Principles of antibiotic therapy. , 1994, The Surgical clinics of North America.

[103]  W. Zimmerli,et al.  Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  A. Hance,et al.  Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. , 1993, Chest.

[105]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[106]  R. Ausman,et al.  Effect of individualized pharmacokinetic dosing on patient outcome , 1991, Critical care medicine.

[107]  R. Milne,et al.  Antibiotic treatment for surgical peritonitis. , 1991, Annals of surgery.

[108]  V L Yu,et al.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. , 1991, Annals of internal medicine.

[109]  L. Navér,et al.  Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. , 1991, The European journal of surgery = Acta chirurgica.

[110]  L. Rice,et al.  Enterococcal endocarditis: a comparison of prosthetic and native valve disease. , 1991, Reviews of infectious diseases.

[111]  M. Fink.  Antibiotic therapy of intra-abdominal sepsis in the elderly: experience with ticarcillin and clavulanic acid. , 1991, Surgery, gynecology & obstetrics.

[112]  J. Solomkin,et al.  Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. , 1990, Annals of surgery.

[113]  C. Feldman,et al.  Klebsiella pneumoniae bacteraemia at an urban general hospital. , 1990, The Journal of infection.

[114]  M. Sande,et al.  TREATMENT OF RIGHT-SIDED STAPHYLOCOCCUS AUREUS ENDOCARDITIS IN INTRAVENOUS DRUG USERS WITH CIPROFLOXACIN AND RIFAMPICIN , 1989, The Lancet.

[115]  V. Yu,et al.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. , 1989, The American journal of medicine.

[116]  L. Baker,et al.  Management of severe intra‐abdominal sepsis: Single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole , 1988, The British journal of surgery.

[117]  N. Christou,et al.  Treatment of severe intra-abdominal sepsis and/or necrotic foci by an 'open-abdomen' approach. Zipper and zipper-mesh techniques. , 1988, Archives of surgery.

[118]  H. Giamarellou.  Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. , 1986, The American journal of medicine.

[119]  G. Eliopoulos,et al.  Beta-lactam/aminoglycoside combinations: interactions and their mechanisms. , 1986, The American journal of medicine.

[120]  G. Ruoff.  The pain of osteoarthritis. , 1986, The American journal of medicine.

[121]  C. Cordon-Cardo,et al.  Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. , 1986, The American journal of medicine.

[122]  R. Weinstein.  Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients. , 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[123]  H. Giamarellou,et al.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.

[124]  Jerome J. Schentag,et al.  A Randomized Clinical Trial of Moxalactam Alone versus Tobramycin plus Clindamycin in Abdominal Sepsis , 1983, Annals of surgery.

[125]  J. Klastersky,et al.  Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin , 1983, Antimicrobial Agents and Chemotherapy.

[126]  M. Sande,et al.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. , 1982, Annals of internal medicine.

[127]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[128]  R. Greenman,et al.  Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. , 1979, Annals of internal medicine.

[129]  W. Hewitt,et al.  Antimicrobial synergism in the therapy of gram-negative rod bacteremia. , 1978, Chemotherapy.

[130]  W. J. Martin,et al.  Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. , 1977, Annals of internal medicine.

[131]  J. Klastersky,et al.  Significance of antimicrobial synergism for the outcome of gram negative sepsis. , 1977, The American journal of the medical sciences.

[132]  C. Watanakunakorn,et al.  Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. , 1977, The American journal of the medical sciences.

[133]  Sande Ma,et al.  Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. , 1976 .

[134]  R. Moellering,et al.  Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. , 1974, The American journal of medicine.

[135]  R. Bryant,et al.  Factors affecting mortality of gram-negative rod bacteremia. , 1971, Archives of internal medicine.

[136]  E. Hook,et al.  Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. , 1970, Archives of internal medicine.

[137]  W. Vogler,et al.  Bacterial endocarditis. A review of 148 cases. , 1962, The American journal of medicine.

[138]  W. J. Martin,et al.  Antibiotic Therapy of Bacterial Endocarditis: VI. Subacute Enterococcal Endocarditis Clinical, Pathologic and Therapeutic Consideration of 33 Cases , 1954, Circulation.